Trial of Efficacy and Safety of NS-229 Versus Placebo in Patients With Eosinophilic Granulomatosis With Polyangiitis

Conditions:   Eosinophilic Granulomatosis With Polyangiitis;   Churg-Strauss Syndrome Interventions:   Drug: NS-229;   Drug: Placebo Sponsors:   NS Pharma, Inc.;   Nippon Shinyaku Co., Ltd. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials